Skip to main content
Top
Published in: Clinical Rheumatology 5/2022

Open Access 01-05-2022 | Systemic Lupus Erythematosus | Brief Report

Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis

Authors: Rebecca Heijke, Mathilda Björk, Ingrid Thyberg, Alf Kastbom, Laura McDonald, Christopher Sjöwall

Published in: Clinical Rheumatology | Issue 5/2022

Login to get access

Abstract

The onset of rheumatic disease affects each patient differently and may impact quality of life with progression. We investigated the relationship between patient-reported outcome measure (PROM) scores and organ damage in patients with recent-onset systemic lupus erythematosus (SLE) and those with early rheumatoid arthritis (RA). Patients with recent-onset SLE without prior organ damage from the Clinical Lupus Register in Northeastern Gothia and patients with early RA from the observational 2nd Timely Interventions in Early RA study, Sweden, were included. Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) was used to assess organ damage. PROM (visual analog scale [VAS]: pain, fatigue, well-being, Health Assessment Questionnaire, and EQ-5D-3L) scores were captured at months 0, 6, 12, 24, 36, 48, and 60 after diagnosis. Statistical tests included Pearson correlation coefficients and t-tests. Forty-one patients with recent-onset SLE and 522 with early RA were included. Numerical differences were seen in age and sex. PROMs were worse for patients with RA versus SLE but improved by month 6 following diagnosis, while SLE PROMs remained stable. The incidence of organ damage in SLE was 13.6 per 100 patient-years. SDI significantly correlated with EQ-5D-3L (− 0.48, P = 0.003), VAS fatigue (0.44, P = 0.009), and well-being (0.41, P = 0.01) at month 24. As illustrated, the complexity of disease burden in patients with SLE is clear and may result from disease-related multiorgan system effects and slower symptom resolution compared with RA. This underscores the need for improved multiprofessional interventions to manage all aspects of SLE.
Key Points
We observed an evident discrepancy in patient-reported outcome measures (PROMs) between patients with recent-onset SLE and early RA.
Despite differences in PROMs between patients with recent-onset SLE and early RA, both groups had prominent self-reported disability during the study period.
PROM scores for patients with RA were generally worse than those with SLE but improved by month 6, whereas PROM scores for patients with SLE remained stable over time.
Our findings underline the need of new therapeutic options and interventions for SLE disease management, including pharmacologic and multiprofessional aspects.
Literature
1.
go back to reference Mahieu M, Yount S, Ramsey-Goldman R (2016) Patient-reported outcomes in systemic lupus erythematosus. Rheum Dis Clin North Am 42:253–263CrossRef Mahieu M, Yount S, Ramsey-Goldman R (2016) Patient-reported outcomes in systemic lupus erythematosus. Rheum Dis Clin North Am 42:253–263CrossRef
2.
go back to reference Björk M, Dahlström Ö, Wetterö J, Sjöwall C (2015) Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord 16:188CrossRef Björk M, Dahlström Ö, Wetterö J, Sjöwall C (2015) Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord 16:188CrossRef
3.
go back to reference Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605–620CrossRef Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605–620CrossRef
4.
go back to reference Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER (2021) The burden of systemic lupus erythematosus in Germany: incidence, prevalence, and healthcare resource utilization. Rheumatol Ther 8:375–393CrossRef Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, Desta B, Hammond ER (2021) The burden of systemic lupus erythematosus in Germany: incidence, prevalence, and healthcare resource utilization. Rheumatol Ther 8:375–393CrossRef
5.
go back to reference Jönsen A, Hjalte F, Willim M et al (2016) Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum 45:684–690CrossRef Jönsen A, Hjalte F, Willim M et al (2016) Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum 45:684–690CrossRef
6.
go back to reference Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30:1955–1959PubMed Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30:1955–1959PubMed
7.
go back to reference Lattanzi B, Consolaro A, Solari N, Ruperto N, Martini A, Ravelli A (2011) Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken) 63(Suppl 11):S112-117CrossRef Lattanzi B, Consolaro A, Solari N, Ruperto N, Martini A, Ravelli A (2011) Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken) 63(Suppl 11):S112-117CrossRef
8.
go back to reference Heijke R, Björk M, Frodlund M, McDonald L, Alemao E, Sjöwall C (2020) Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus 29:625–630CrossRef Heijke R, Björk M, Frodlund M, McDonald L, Alemao E, Sjöwall C (2020) Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus 29:625–630CrossRef
9.
go back to reference Hiligsmann M, Rademacher S, Kaal KJ, Bansback N, Harrison M (2018) The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. Semin Arthritis Rheum 48:357–366CrossRef Hiligsmann M, Rademacher S, Kaal KJ, Bansback N, Harrison M (2018) The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. Semin Arthritis Rheum 48:357–366CrossRef
10.
go back to reference Ziegelasch M, van Delft MA, Wallin P, Skogh T, Magro-Checa C, Steup-Beekman GM, Trouw LA, Kastbom A, Sjöwall C (2016) Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther 18:289CrossRef Ziegelasch M, van Delft MA, Wallin P, Skogh T, Magro-Checa C, Steup-Beekman GM, Trouw LA, Kastbom A, Sjöwall C (2016) Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther 18:289CrossRef
11.
go back to reference Antonini L, Le Mauff B, Marcelli C, Aouba A, de Boysson H (2020) Rhupus: a systematic literature review. Autoimmun Rev 19:102612CrossRef Antonini L, Le Mauff B, Marcelli C, Aouba A, de Boysson H (2020) Rhupus: a systematic literature review. Autoimmun Rev 19:102612CrossRef
12.
go back to reference Versteeg GA, Steunebrink LMM, Vonkeman HE, Ten Klooster PM, van der Bijl AE, van de Laar M (2018) Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol 37:1189–1197CrossRef Versteeg GA, Steunebrink LMM, Vonkeman HE, Ten Klooster PM, van der Bijl AE, van de Laar M (2018) Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol 37:1189–1197CrossRef
13.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRef
14.
go back to reference Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRef Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRef
15.
go back to reference Fanouriakis A, Bertsias G (2019) Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med 6:e000310CrossRef Fanouriakis A, Bertsias G (2019) Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med 6:e000310CrossRef
16.
go back to reference Combe B, Landewe R, Daien CI et al (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959CrossRef Combe B, Landewe R, Daien CI et al (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959CrossRef
17.
go back to reference Martinsson K, Johansson A, Kastbom A, Skogh T (2017) Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project). Clin Exp Immunol 188:53–62CrossRef Martinsson K, Johansson A, Kastbom A, Skogh T (2017) Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project). Clin Exp Immunol 188:53–62CrossRef
18.
go back to reference Greenfield J, Hudson M, Vinet E, Fortin PR, Bykerk V, Pineau CA, Wang M, Bernatsky S, Baron M (2017) A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). PLoS One 12:e0189840CrossRef Greenfield J, Hudson M, Vinet E, Fortin PR, Bykerk V, Pineau CA, Wang M, Bernatsky S, Baron M (2017) A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). PLoS One 12:e0189840CrossRef
19.
go back to reference Grassi W, De Angelis R, Lamanna G, Cervini C (1998) The clinical features of rheumatoid arthritis. Eur J Radiol 27(Suppl 1):S18-24CrossRef Grassi W, De Angelis R, Lamanna G, Cervini C (1998) The clinical features of rheumatoid arthritis. Eur J Radiol 27(Suppl 1):S18-24CrossRef
20.
go back to reference Ekdahl C, Eberhardt K, Andersson SI, Svensson B (1988) Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 17:263–271CrossRef Ekdahl C, Eberhardt K, Andersson SI, Svensson B (1988) Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 17:263–271CrossRef
21.
go back to reference Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRef Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRef
22.
go back to reference Lati C, Guthrie LC, Ward MM (2010) Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis. J Rheumatol 37:717–722CrossRef Lati C, Guthrie LC, Ward MM (2010) Comparison of the construct validity and sensitivity to change of the visual analog scale and a modified rating scale as measures of patient global assessment in rheumatoid arthritis. J Rheumatol 37:717–722CrossRef
23.
go back to reference Maska L, Anderson J, Michaud K (2011) Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken) 63(Suppl 11):S4-13CrossRef Maska L, Anderson J, Michaud K (2011) Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken) 63(Suppl 11):S4-13CrossRef
24.
go back to reference Coretti S, Ruggeri M, McNamee P (2014) The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res 14:221–233CrossRef Coretti S, Ruggeri M, McNamee P (2014) The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res 14:221–233CrossRef
25.
go back to reference Stauffer ME, Taylor SD, Watson DJ, Peloso PM, Morrison A (2011) Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale. Int J Inflam 2011:231926PubMedPubMedCentral Stauffer ME, Taylor SD, Watson DJ, Peloso PM, Morrison A (2011) Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale. Int J Inflam 2011:231926PubMedPubMedCentral
26.
go back to reference Elera-Fitzcarrald C, Vega K, Gamboa-Cárdenas RV et al (2020) Reliability of visual analog scale and numeric rating scale for the assessment of disease activity in systemic lupus erythematosus. J Clin Rheumatol 26:S170–S173CrossRef Elera-Fitzcarrald C, Vega K, Gamboa-Cárdenas RV et al (2020) Reliability of visual analog scale and numeric rating scale for the assessment of disease activity in systemic lupus erythematosus. J Clin Rheumatol 26:S170–S173CrossRef
27.
go back to reference Wolfe F, Michaud K, Pincus T (2005) Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 32:1261–1266PubMed Wolfe F, Michaud K, Pincus T (2005) Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 32:1261–1266PubMed
28.
go back to reference Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, Højbjerre L, Strandberg-Larsen M, Hansen BB (2014) Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes 12:116CrossRef Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, Højbjerre L, Strandberg-Larsen M, Hansen BB (2014) Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes 12:116CrossRef
29.
go back to reference Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36:551–559CrossRef Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36:551–559CrossRef
30.
go back to reference Milligan SE, Hom DL, Ballou SP, Persse LJ, Svilar GM, Coulton CJ (1993) An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. J Rheumatol 20:972–976PubMed Milligan SE, Hom DL, Ballou SP, Persse LJ, Svilar GM, Coulton CJ (1993) An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. J Rheumatol 20:972–976PubMed
31.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef
32.
go back to reference Burström K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621–635CrossRef Burström K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621–635CrossRef
Metadata
Title
Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis
Authors
Rebecca Heijke
Mathilda Björk
Ingrid Thyberg
Alf Kastbom
Laura McDonald
Christopher Sjöwall
Publication date
01-05-2022
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 5/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05982-3

Other articles of this Issue 5/2022

Clinical Rheumatology 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine